The EMA has started its review of Daiichi Sankyo and AstraZeneca's Enhertu as a first-line therapy for HER2-positive breast cancer, setting up a possible approval later this year. The two companies ...

England is the first country in the world to make GSK's anti-BCMA drug Blenrep available to patients with the haematological cancer multiple myeloma, in the latest stage of the medicine's renaissance.